220 related articles for article (PubMed ID: 35076853)
41. Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells.
Thulasiraman P; McAndrews DJ; Mohiudddin IQ
BMC Cancer; 2014 Sep; 14():724. PubMed ID: 25260874
[TBL] [Abstract][Full Text] [Related]
42. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
[TBL] [Abstract][Full Text] [Related]
43. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
Lee JO; Kang MJ; Byun WS; Kim SA; Seo IH; Han JA; Moon JW; Kim JH; Kim SJ; Lee EJ; In Park S; Park SH; Kim HS
Breast Cancer Res; 2019 Oct; 21(1):115. PubMed ID: 31640742
[TBL] [Abstract][Full Text] [Related]
44. Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer.
Guney Eskiler G; Sahin E; Deveci Ozkan A; Cilingir Kaya OT; Kaleli S
Nutr Cancer; 2020; 72(6):1057-1066. PubMed ID: 31573354
[TBL] [Abstract][Full Text] [Related]
45. Synergistic effect of anethole and doxorubicin alleviates cell proliferation, cell cycle arrest, and ER stress and promotes ROS-mediated apoptosis in triple-negative breast cancer cells.
Arumugam P; Sampathkumar B; Perumalsamy H; Balusamy SR; Ramesh V; Sundaravadevel S
J Biochem Mol Toxicol; 2021 Dec; 35(12):e22928. PubMed ID: 34585488
[TBL] [Abstract][Full Text] [Related]
46. Photodynamic treatment with anionic nanoclays containing curcumin on human triple-negative breast cancer cells: Cellular and biochemical studies.
Khorsandi K; Hosseinzadeh R; Shahidi FK
J Cell Biochem; 2019 Apr; 120(4):4998-5009. PubMed ID: 30302810
[TBL] [Abstract][Full Text] [Related]
47. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
48. Andrographolide sensitizes Hep-2 human laryngeal cancer cells to carboplatin-induced apoptosis by increasing reactive oxygen species levels.
Mao W; He P; Wang W; Wu X; Wei C
Anticancer Drugs; 2019 Aug; 30(7):e0774. PubMed ID: 31306153
[TBL] [Abstract][Full Text] [Related]
49. Diterpenoid natural compound C4 (Crassin) exerts cytostatic effects on triple-negative breast cancer cells via a pathway involving reactive oxygen species.
Richards CE; Vellanki SH; Smith YE; Hopkins AM
Cell Oncol (Dordr); 2018 Feb; 41(1):35-46. PubMed ID: 29134467
[TBL] [Abstract][Full Text] [Related]
50. Myricetin-induced apoptosis of triple-negative breast cancer cells is mediated by the iron-dependent generation of reactive oxygen species from hydrogen peroxide.
Knickle A; Fernando W; Greenshields AL; Rupasinghe HPV; Hoskin DW
Food Chem Toxicol; 2018 Aug; 118():154-167. PubMed ID: 29742465
[TBL] [Abstract][Full Text] [Related]
51. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
52. Knockdown of CAVEOLIN-1 Sensitizes Human Basal-Like Triple-Negative Breast Cancer Cells to Radiation.
Zou M; Li Y; Xia S; Chu Q; Xiao X; Qiu H; Chen Y; Zheng Z; Liu F; Zhuang L; Yu S
Cell Physiol Biochem; 2017; 44(2):778-791. PubMed ID: 29169152
[TBL] [Abstract][Full Text] [Related]
53. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
54. Rad51 Silencing with siRNA Delivered by Porous Silicon-Based Microparticle Enhances the Anti-Cancer Effect of Doxorubicin in Triple-Negative Breast Cancer.
Wu Z; Zhu L; Mai J; Shen H; Xu R
J Biomed Nanotechnol; 2021 Dec; 17(12):2351-2363. PubMed ID: 34974858
[TBL] [Abstract][Full Text] [Related]
55. F1012-2 Induced ROS-Mediated DNA Damage Response through Activation of MAPK Pathway in Triple-Negative Breast Cancer.
Dai L; Tian S; Zhang J; Lu M; Zhu J; Zhao H
Biomed Res Int; 2021; 2021():6650045. PubMed ID: 34124254
[TBL] [Abstract][Full Text] [Related]
56. Mitochondrial dynamics as a novel treatment strategy for triple-negative breast cancer.
Wang Y; Harada-Shoji N; Kitamura N; Yamazaki Y; Ebata A; Amari M; Watanabe M; Miyashita M; Tada H; Abe T; Suzuki T; Gonda K; Ishida T
Cancer Med; 2024 Jan; 13(2):e6987. PubMed ID: 38334464
[TBL] [Abstract][Full Text] [Related]
57. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
[TBL] [Abstract][Full Text] [Related]
58. Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5.
Kamalabadi-Farahani M; H Najafabadi MR; Jabbarpour Z
Asian Pac J Cancer Prev; 2019 Jun; 20(6):1743-1748. PubMed ID: 31244295
[TBL] [Abstract][Full Text] [Related]
59. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
60. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
